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ABSTRACT 
Background: Peripheral neuropathy can be caused by diabetes mellitus, nutritional 
deficiencies, entrapment or Carpal Tunnel Syndrome (CTS), and idiopathic. 
Objective: To determine the therapeutic efficacy of Vitamin B1, B6, and B12 forte 
in relieving symptoms of peripheral neuropathy. 
Methods: This was pre- and post-experimental study involving patients with 
moderate peripheral neuropathy (Toronto Clinical Neuropathy Score [TCNS] ≥6 and 
Michigan Neuropathy Screening Instrument [MNSI] ≥7) taken from outpatient 
neurological clinic of Dr. Kariadi Hospital, Semarang. The patient was prescribed 
vitamin B1 100 mg, B6 100 mg, and B12 5000 mcg once daily for 2 months. 
Evaluation of the numerical pain rating scale in the form of VAS and Total Symptom 
Score (TSS) was conducted at the first and second month. The VAS score difference 
test was conducted with the Wilcoxon test and TSS with the Post Hoc test and 
considered significant if p <0.05. 
Results:  There were 30 patients aged 18 - 65 years, consisted of 70% female and 
30% male. The etiology of peripheral neuropathy was idiopathic (40%), CTS 
(26.7%), DM (23.3%), and HNP (10%). There were significant differences of the 
VAS scale and TSS at every evaluation. 
Conclusion: Administration of VitB1, B6, and B12 forte relieved symptoms of 
moderate peripheral neuropathy with improvement of VAS and TSS scores. 
 






The definition of neuropathic pain according to 
the International Association for the Study of Pain 
(LASP) is pain triggered by a primary lesion or 
dysfunction of the nervous system and can be 
caused by compression or infiltration of the nerves 
depending on its location. It can be defined as an 
abnormal pain that occurs either as a result of 
lesions of the peripheral or central nervous system. 
The prevalence is approximately 1.5% of all 
population in the United States. Several diseases 
can manifest as neuropathic pain, such as trigeminal 
neuralgia, diabetic neuropathy, spinal cord injury, 
cancer, stroke, and degenerative neurological 
disease.1   
According to Attal et al, the incidence of 
neuropathic pain was also found to be quite high in 
Europe, namely 7-8% of the general population.2 In 
Indonesia, based on the results of a multicenter 
outpatient study in 14 teaching hospitals conducted 
by the Pokdi Nyeri PERDOSSI, there were 4,456 
cases of pain, 9.5% were neuropathic pain. In 2012,  
the cases increased up to 21.8% based on the study 
in 13 hospital with more sensitive screening 
instruments.3 Most of subjects were men (62.1%) 
aged 40-60 years with low back pain, carpal tunnel 
syndrome, frozen shoulder, diabetic neuropathy, 
and brachialgia.4 Neuropathic pain will also affect 
the quality of life and sleep. Bartley, et al stated that 
severe and chronic neuropathic pain could increase 
the risk of anxiety, depression, and decreased 
quality of life. Choi, et al also reported that of all 
subjects with neuropathic pain, 67.3% experienced 
moderate to severe pain; 43.5% showed prolonged 
pain over two years; and 32.4% suffered from sleep 
disturbances due to pain, and 22.8% of patients 
were  dissatisfied with the current management of 
pain.5 
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Pain sensation is normally initiated by activity on 
afferent unmyelinated (C-) and thinly myelinated 
(Aδ-) nerves. These nociceptors will usually not be 
excited without external stimulation. However, when 
peripheral nerve lesions occur, these neurons may 
become abnormally sensitive and develop 
pathological spontaneous neurological activity.6 
The spontaneous ectopic activity in damaged 
nerve cells also indicates an increase of m-RNA 
expression for voltage-gated sodium channels. This 
group of sodium channels at ectopic site is responsible 
for the low threshold of action potential and 
hyperactivity. This can cause sensitivity to stimuli. 
Thus, when there is a stimulus that normally does not 
cause pain, it can immediately cause excessive pain 
instead.6 
Lesions in nerve cells will cause regeneration 
and the growth of neuromas in its proximal part. 
Abnormal excitation and discharge can appear in this 
neuroma. This can cause spontaneous abnormal pain 
in the neuropathic patient.1,6 
After a nerve cell lesion occurs, the activated 
macrophage will enter the endoneural blood vessel 
into the nerve and release cytokines. This 
inflammatory mediator will induce ectopic activity on 
damaged nerve cells as well as nearby normal nerve 
cells. Patients with inflammatory neuropathies will 
experience very deep pain.6 
As a consequence of peripheral nociceptor 
hyperactivity, a dramatic secondary change occurs in 
the dorsal horn of the spinal cord. Lesions of the 
peripheral nerves will increase the excitation ability 
of multireceptors in spinal cord neurons (wide-
dynamic-range neurons). This hyperexcitation is 
manifested by increased nerve cell activity in 
response to noxious stimulation, expansion of the 
receptive neuronal field, and the spread of spinal 
hyperexcitation to other segments.6 
Under normal circumstances, neurons in the 
dorsal horn will receive a strong inhibition from 
GABA (gamma-aminobutyric acid). In animal study, 
partial nerve injury will initiate apoptosis of GABA in 
the superficial portion of the neuron in the dorsal 
horn. This increases the pain stimulation a 
neuropathic patient will receive. 
Pharmacotherapy that can be used to relieve 
neuropathic symptoms are anticonvulsants, 
antidepressants, and neurotropics agent, which 
include vitamins B1, B6, and B12. Neurotropic 
vitamins is meant to normalize nerve function by 
improving metabolic disorders by providing the 
required intake.3 Administration of vitamins B1 
(100mg), B6 (100mg), and B12 (200mcg) has been 
shown to be effective in neuropathic symptoms.7 
There was still a few data regarding vitamins B1, B6, 
and B12 as determinants factors of peripheral 
neuropathy symptoms reduction (pain, burning, 
tingling, and numbness), as well as the increasing 
incidence of peripheral neuropathy. Thus, we want to 
know more about the effects of vitamins B1, B6, and 
B12 to symptoms of peripheral neuropathy (pain, 
burning, tingling and numbness). 
2. Methods 
This was a prospective cohort experimental 
study with consecutive sampling method and a 
sample size of 30. It was conducted in the outpatient 
neurology clinic Dr. Kariadi Hospital, Semarang by 
using a pre and post-test design. Subjects diagnosed 
with peripheral neuropathy who met the inclusion 
criteria were given vitamins B1, B6, B1 vitamin B1 
(100mg), B6 (100mg), B12 (5000mcg) for 2 months. 
Evaluation and measurement of the neuropathy 
degree were carried out on days 0, 30, and 60. The 
inclusion criteria were aged 19-64 years; willing to be 
the subjects; suffering from moderate peripheral 
neuropathy (MNSI Score> = 7) or TCNS> = 6; 
various etiologies, such as diabetes mellitus, 
nutritional, CTS, idiopathic, etc.) Meanwhile, the 
exclusion criteria were history of cardiovascular, 
respiratory, gastrointestinal, hematological, hepatic, 
renal or endocrine disease (except diabetes mellitus); 
received methotrexate therapy or other cytostatic 
drugs; hypersensitivity to Vit B1, B6, B12 forte; 
suspected of having inherited neuropathy; in 
pregnancy or breastfeeding; underwent 
gastrointestinal surgery at least 6 months before the 
study; had mental illness or in psychiatric therapy; 
had received NSAIDs, gabapentin, pregabalin, or 
other anti-inflammatory drugs due to severe 
neuropathy (TCNS> = 12, VAS> = 7); or had taken 
oral or parenteral Vit B complex (Vit B1 100-300mg, 
B6 50-600mcg, B12 200-5000mcg) for more than 1 
week in the last 3 months before the study. 
The method of diagnosis used the Michigan 
Neuropathy Screening Instrument (MNSI) and the 
Toronto Clinical Neuropathy Score (TCNS). The 
improvement of neuropathy symptoms was assessed 
at each visit using the VAS scale and Total Symptom 
Score (TSS) by assessing symptoms including pain 
intensity, burning, tingling, and numbness. The total 
symptoms score data was then compared at each visit 
to see if there were significant reductions in 
neuropathy symptoms after the use administration of 
vitamin B1, B6 and B12 therapy. The VAS score 
difference test was conducted with Wilcoxon test and 
TSS with the Post Hoc test, and considered to be 
significant if p <0.05. 
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In this study (Table 1), it was found that the 
subjects were predominantly female (70%) and 
idiopathic etiology (40%) with a mean age of 52.9 
years. The etiology of all the subjects consisted of 
carpal tunnel syndrome (26.7%), diabetes mellitus 
(23%), and hernia nucleus pulposus (10%), 
respectively. There were also patients with risk 
factors that could affect the outcome of the study, they 
were hypertension (60%), smoking (30%), alcohol 
(3.3%), and consumption of tea or coffee (100%). 
 
Table 1. Characteristics of the subjects with peripheral 
neuropathy 





Sex     
 Male 9 30   
 Female 21 70   
Age   
52.90 ± 
5.79 
55 (36 – 
61) 
Etiology     
 DM 7 23.3   
 HNP 3 10   
 CTS 8 26.7   
 Idiopathic 12 40   
Subjective MNSI    
7.90 ± 
1.09 
8 (6 – 
10) 
Objective MNSI    
1.20 ± 
6.66 
1 (0 – 3) 
TCNS   
7.83 ± 
1.05 
8 (6 – 
11) 
Hypertension 18 60   
Smoking 9 30   
Alcohol 1 3.3   
Tea and coffee 
consumption 
30 100   
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Table 2 showed that there were significant 
differences in the mean VAS and TSS score of all 
subjects with peripheral neuropathy of various 
etiologies who received B1, B6, B12 forte therapy, 
both from monitoring at the first month compared to 
the time of diagnosis (p <0.05), the second month 
compared to the first month (p <0.05), as well as the 
second month compared to the start of the study (p 
<0.05). 
 
Table 2. The differences of VAS and TSS score among 
visits 
Variable 
Mean ± SD 
(Range) 
P 
P value between visits 
1 – 2 2 – 3 1 – 3 
VAS      
VAS 1 
3.75 ± 0.58 
(3.1 – 4.8) 
0.00*¥ 0.00*£ 0.00*£ 0.00*£ VAS 2 
2.71 ± 0.48 
(2.1 – 3.6) 
VAS 3 
2.19 ± 0.41 
(1.5 – 2.8) 
TSS      
TSS 1 
7.37 ± 1.18 
(5.65 – 
10.3) 
0.00*§ 0.00*‡ 0.00*‡ 0.00*‡ TSS 2 




3.87 ± 1.04 
(2.33 – 
5.65) 
Note: * Significant; ¥ Friedman; £ Wilcoxon; § Repeated Anova; 
‡ Post Hoc 
 
Table 3 showed an improvement in VAS score 
both for patients who have risk factors or not. 
 
Table 3. The effects of risk factors to VAS score among 
visits 
Variable 
P value of VAS between visits 
1 – 2 2 – 3 1 – 3 
p P p 
Hypertension 0.137‡ 0.829‡ 0.120‡ 
Smoking 0.958§ 0.088‡ 0.649‡ 
Alcohol 
consumption 
0.643‡ 0.141‡ 0.384‡ 
Note: § t-test; ‡ Mann Whitney 
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Figure 1. The effect of risk factors to VAS score among 
visits 
 
Table 4 showed that there was an improvement 
in the TSS score and significant differences of TTS in 
subjects who had a risk factor of smoking. In subjects 
with hypertension, there was a significant difference 
at the first visit compared to after receiving Vit B1, 
B6, B12 Forte for 2 months. 
 
Table 4. The effects of risk factors to TSS among visits 
Variable 
P value of TSS between visits 
1 – 2 2 – 3 1 – 3 
p P p 
Hypertension 0.202§ 0.098‡ 0.020*§ 
Smoking 0.024*§ 0.005*‡ 0.000*§ 
Alcohol 
consumption 
0.415‡ 1.000‡ 0.418‡ 
Note: * Significant; § t-test; ‡ Mann Whitney; ¥ Spearman’s; 
¶ Kruskal Wallis; ☼ ANOVA 
 
 
Figure 2. The effect of risk factors to TTS among visits 
4. Discussion 
The hypothesis in this study was administration 
of vitamins B1, B6 and B12 Forte had an effect on 
reducing the symptom score of VAS or TSS in 
patients with peripheral neuropathy. TTS was chosen 
because we could directly observe 4 symptoms at 
once in neuropathic patients. 
The total number of patients in this study was 30 
patients with 21 female (70%) and 9 male (30%). This 
was similar to Katulanda et al. which stated that the 
prevalence of patients suffering from diabetic 
neuropathy in developing countries was 
predominantly female.8 This is also consistent with 
other studies on the epidemiology of neuropathic pain 
by Fillingim et al. and Bartley et al. They found that 
sensitivity to pain occurred more frequently in female 
than male.9,10 This could be the result of many factors, 
including biopsychosocial, hormones, and pain 
coping. Meanwhile, the mean age of the subjects in 
this study was 52 years. It was similar to a study by 
Perhimpunan Dokter Spesialis Saraf Indonesia which 
was conducted on 5,000 patients in hospitals in 
Jakarta, Surabaya, and Medan, which reported that 
81% of neuropathy attacked patients who were 40 
years old and older.3 Lautenbacher et al. and Wandner 
et al. indicated that old age patients had a higher pain 
sensitivity than younger. These studies also stated that 
the perception of pain or discomfort showed less 
consistent results in the younger age patients.11,12  
Smoking is a modifiable risk factor for diabetic 
neuropathy. According to the Center for Disease 
Control and Prevention (CDC), smoking will increase 
nerve damage in diabetic patients causing 
complications of peripheral neuropathy with 
symptoms of numbness, pain, lack of coordination, 
and weakness in hands and feet.13 Tesfaye et al. stated 
that the incidence of diabetic neuropathy was 
multifactorial related to metabolic disorders, 
oxidative stress, and growth factor deficiency.13 
Wiggin et al. also reported that high triglyceride was 
the only clinical parameter correlated with the loss of 
nerve fiber density in diabetic neuropathy patients.14 
This was because therapy was meant to control blood 
lipid level and administration of vitamin combination 
for 2 weeks helped in decreasing the total symptom 
score.14 Theoretically, hypertension and high blood 
sugar can accelerate microvascular and 
macrovascular complications that lead to nerve fiber 
damage and causing neuropathic symptoms.15 This is 
in line with this study, which showed that there was a 
significant relationship between the difference of TSS 
among visits and  smoking as risk factor. Meanwhile, 
there was no statistically significant association 
between the risk factors of smoking, hypertension, 
and alcohol consumption with the VAS difference 
among visits although there was an improvement in 
the VAS score. 
This study did not measure the patient's blood 
sugar levels. According to the National Institute of 
Diabetes and Digestive and Kidney Diseases 
(NIDDK), the best way to prevent and improve 
neuropathy was by controlling blood sugar levels 
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All samples in this study were given combination 
therapy of vitamins B1 (100 mg), B6 (100 mg), and 
B12 (5000 mcg) forte once a day. In general, there 
were no serious side effects from the administration 
this vitamin. Three of the 30 samples had reactions to 
vitamin B therapy, including nausea and vomiting. 
Vitamin B12 plays a role in the metabolism of fatty 
acids which are useful in repairing nerve myelin fibers. 
The role of vitamin B1 is to initiate nerve impulses 
from coenzymes and B6 is involved in the synthesis 
of neurotransmitters so that both of them can improve 
neuropathy17. 
This study showed that there was a decrease in 
TSS after giving combination therapy of vitamins B1, 
B6 and B12 either after 30 days or 60 days. This was 
in accordance with the Farvid et al. They conducted a 
study with administration of B1 (10 mg), B2 (10 mg), 
B6 (10 mg), biotin (200 mg), B12 (10 mg) and folic 
acid (1 mg) supplementation and assessed by 
Michigan Neuropathy Screening Instrument (MNSI). 
It obtained a significant decrease of MNSI score from 
3.96 to 1.00 (p = 0.01).18 A significant result was also 
found by Rizvi et al., a combination of vitamins B1 
(100mg), B6 (100mg), and B12 (200mcg) was 
effective in 177 (57%) of 310 patients with diabetic 
peripheral neuropathy.7 
5. Conclusion 
The administration of vitamins B1, B6 and B12 
forte therapy has been shown to have an effect on the 
clinical outcome of patients with peripheral 
neuropathy with various etiologies. However, further 
research is still needed to assess other risk factors such 
as dyslipidemia, blood sugar levels, etc., comparing 
between etiologies, and the magnitude of the effect 
based on existing risk factors.  
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